Ferritin Nanoparticle Epitope Display for Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods face challenges in effectively transporting cancer-specific antigens to lymph nodes, leading to inadequate immune responses due to short antigen peptide lengths and limitations in uniformly exposing antigens on polymer carriers.
Innovation Solution
A recombinant microorganism is developed with a vector linking a human ferritin heavy chain protein gene and a cancer-specific epitope gene, producing protein nanoparticles that target lymph nodes with high efficiency and stability, allowing for effective cancer immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If only cancer-specific antigen peptide is administered for immunotherapy, then the treatment targets cancer specifically, but the immune response is insufficient due to short peptide length
Solution Approach 1:
The patent combines cancer-specific antigen peptides with ferritin protein nanocages to create a composite nanoparticle system. The ferritin nanocage serves as a carrier that displays multiple antigen peptides on its surface, creating a composite structure that maintains cancer specificity while amplifying immune response through multivalent presentation
Solution Approach 2:
The antigen is segmented into multiple short peptides that are independently displayed on the ferritin nanocage surface. This segmentation allows each peptide to maintain its specific cancer-targeting capability while the collective array of peptides on the nanocage surface provides enhanced immune stimulation
2Ease of operation
If polymer carriers are used to transport cancer antigen, then the antigen can be delivered to lymph nodes, but the antigen exposure is non-uniform due to chemical bonding limitations
Solution Approach 1:
The ferritin protein nanocage self-assembles into a regular 24-subunit structure that automatically provides uniform spacing and orientation of antigen peptides on its surface. This self-organizing property eliminates the need for complex chemical bonding procedures and ensures uniform antigen exposure without requiring precise manufacturing control
Solution Approach 2:
The patent changes the carrier material from synthetic polymer to protein-based ferritin, which fundamentally alters the antigen attachment mechanism from chemical bonding to protein-protein interaction. This parameter change enables uniform antigen display through the inherent structural regularity of ferritin's 24-subunit assembly
3Ease of operation
If existing nanoparticle systems are used for antigen delivery, then lymph node targeting is achieved, but structural stability and toxicity issues limit therapeutic effectiveness
Solution Approach 1:
The patent uses ferritin, a naturally occurring protein that is biodegradable and non-toxic, replacing synthetic nanoparticles with long-lasting structural concerns. The ferritin nanocage acts as a temporary delivery vehicle that safely degrades after delivering its antigen payload to lymph nodes, eliminating long-term toxicity concerns
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The protein nanoparticles demonstrate excellent lymph node targeting and immune response activation, reducing tumor size and generating robust immune responses without toxicity, outperforming existing nanoparticle-based immunotherapies.
Implementation Method 1
ferritin is formed of 24 identical protein subunits consisting of heavy chains and light chains, and forms a hollow shell in a living body
Data Source
AI summary
The present invention relates to a protein nanoparticle having a surface on which a cancer-specific epitope is fused and expressed, a method for producing the same, and a composition for cancer immunotherapy containing the protein nanoparticle as an active ingredient, and more specifically, to a recombinant microorganism into which a vector in which a promoter, a gene of a human ferritin heavy chain protein, and a gene encoding the cancer-specific epitope are operably linked is introduced, a protein nanoparticle in which a cancer-specific epitope is fused and expressed on a surface of the human ferritin heavy chain protein, a method of producing the protein nanoparticle, and a composition for cancer immunotherapy including the protein nanoparticle as the active ingredient, wherein the cancer-specific epitope on the surface of the protein nanoparticle according to the present invention is able to be expressed with correct orientation and high density, and the composition for cancer immunotherapy including the protein nanoparticle as the active ingredient has significantly excellent cancer immunotherapeutic effect as compared to the existing nanoparticle-based composition.